CAR-T is an acronym for chimeric antigen receptor T-cell. The idea is that the body’s naturally occurring T-cells are reprogrammed to attack cancer. The T-cells can be harvested from the patient or another donor. If the therapy is working correctly, only the cancer cells are targeted and healthy cells are unaffected.
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated